Role of Triggering Receptor Expressed on Myeloid Cells (TREM-1) as a Novel Biomarker in Human Epidermal Growth Factor Receptor -2 (HER-2) Negative Breast Cancer: a Molecular and Clinical Study

Launched by RAHMA ESAM SALAMA ESAWI · Apr 27, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating a specific marker called TREM-1 in patients with HER2-negative breast cancer, which is a type of breast cancer that accounts for about 80% of cases. The researchers want to understand how TREM-1 might help doctors predict how well patients will respond to treatment and what their chances of survival might be. This is particularly important for women with either triple-negative or hormone-positive breast cancer, as these groups currently have fewer targeted treatment options.

To participate in this study, women aged 18 and older with confirmed HER2-negative breast cancer who are planning to receive initial treatment (called neo-adjuvant therapy) may be eligible. However, those with breast cancer that has spread to other parts of the body or those with HER2-positive cancer cannot take part. Participants will have their medical information collected and analyzed to see how TREM-1 levels relate to their treatment outcomes. This research aims to improve how breast cancer is managed and could lead to better treatment strategies for patients in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • female patient aged \< 18 yrs. old
• • histological proven breast cancer
• • HER-2 negative (hormonal positive or triple negative)
• • planned to receive neo-adjuvant therapy
• • complete clinical, radiological and therapeutic data
• Exclusion Criteria:
• • metastatic breast cancer
• • HER-2 positive
• • incomplete clinical, radiological or therapeutic data